Signals Inbox·September 2, 2026·MedTech

Why is Medtronic investing in a Chinese robot?

Medtronic is investing about $700 million in Cornerstone Robotics to buy speed: Sentire gives it a second surgical robot, a lower-cost Chinese manufacturing base, existing international approvals and a much faster way to challenge Intuitive while Hugo is still scaling.

Q1What exactly did Medtronic buy from Cornerstone Robotics?

Medtronic has just committed about $700 million to Cornerstone Robotics, giving it an investment in the company and the right to distribute Cornerstone's Sentire surgical robot in selected markets outside the United States.

Medtronic will sell Sentire alongside Hugo, its own robotic-assisted surgery system. The company has not disclosed the exact percentage of Cornerstone it will own, so we cannot calculate the valuation Medtronic placed on the startup from the public information.

The distribution rights are the immediate prize. Sentire already has regulatory approval in China and Singapore and received a European CE Mark covering general surgery, gynecology, thoracic surgery and urology. Medtronic can therefore take an existing robot into approved markets through a sales and service network that already reaches hospitals around the world.

The investment goes deeper than a normal distribution agreement. On Medtronic's latest earnings call, management said it will have a seat on Cornerstone's board and gain a much closer look at how the company operates. For now, Medtronic gets access to the robot without taking on the risk of buying the whole company.

Q2How Chinese is Cornerstone Robotics, really?

Cornerstone Robotics is best understood as a Hong Kong surgical robotics company built around a mainland Chinese manufacturing base.

Samuel Au founded Cornerstone in Hong Kong after spending years at Intuitive Surgical, where he worked on the da Vinci Single-Site platform and was part of the early team behind the technology that became the Ion robotic bronchoscopy system. He later returned to the Chinese University of Hong Kong and founded Cornerstone in 2019.

The manufacturing side sits in Shenzhen. Au told the South China Morning Post that more than 200 engineers work with nearby suppliers around a roughly 150,000-square-foot plant capable of producing about 200 robotic systems a year. A Sentire system contains around 13,000 components, and Cornerstone deliberately built much of that supply chain locally.

The interesting part is the combination. The engineering roots come partly from Silicon Valley and Hong Kong medical robotics, while the manufacturing economics come from Shenzhen and its dense hardware supply chain.

That mix helps explain why Cornerstone could become useful outside China too.

Q3Does Medtronic's Cornerstone deal mean Hugo is in trouble?

Medtronic is still clearly committed to Hugo, and the latest numbers make the Cornerstone investment look like expansion rather than a rescue plan.

CEO Geoff Martha faced this exact question on Medtronic's latest earnings call. His answer was unusually direct. Medtronic expects Hugo to pass 50,000 cumulative procedures and reach around 250 installed systems by the end of its fiscal year. Hugo is already being used in more than 35 countries, and Medtronic says its procedure volume is currently growing at more than twice the overall robotic-surgery market rate.

The company is also spending more on Hugo. New instruments are coming, including integrated stapling and vessel sealing. Medtronic has filed to expand Hugo's U.S. indications beyond urology into general and gynecologic surgery. Its Touch Surgery software is increasingly being connected to the robotic platform too.

Those are expensive commitments for a product a company plans to wind down.

What has changed is Medtronic's ambition. Management now talks openly about becoming a meaningful number two in soft-tissue robotics. Cornerstone gives Medtronic another way to get there without waiting for Hugo to cover every hospital, specialty and price point by itself.

Q4Why does Medtronic want both Hugo and Sentire?

Medtronic wants Hugo and Sentire because the two surgical robots give hospitals meaningfully different ways to build a robotic program.

Hugo has four independent robotic arm carts and an open surgeon console. A hospital can move the carts between operating rooms, change their positioning depending on the procedure and use only the arms it needs. The surgeon remains visually connected to the rest of the operating-room team.

Sentire uses a more immersive console and offers dual-console capability. Its setup feels closer to the closed-console experience many robotic surgeons already know.

There is a practical commercial advantage here. A hospital that dislikes Hugo's modular carts may still be a Medtronic customer for Sentire. Another hospital may specifically want Hugo's flexibility. Medtronic can now have that conversation without losing the customer immediately to another robotic manufacturer.

Medtronic also sells staplers, energy devices, instruments, software, training and other surgical products around the robot. Owning the customer relationship can ultimately be worth much more than the initial machine sale.

Medtronic Hugo vs Cornerstone Sentire

Q5Why is Medtronic keeping Sentire outside the U.S. for now?

Medtronic can move much faster with Sentire outside the U.S. because Cornerstone has already done a large part of the regulatory work there.

Sentire currently has approval in China and Singapore and a European CE Mark across four major surgical specialties. The U.S. is absent from Medtronic's announced distribution agreement.

Hugo is in almost the opposite position strategically. Its U.S. clearance is now a major focus for Medtronic, starting with urologic surgery and expanding through additional regulatory submissions.

This gives Medtronic a fairly clean split today. Hugo carries the U.S. push while Sentire can help Medtronic attack selected international markets where approval already exists.

Time has real value here. A new surgical robot can spend years moving through engineering validation, clinical trials and country-by-country regulatory reviews. Cornerstone has already crossed several of those hurdles.

The international focus also fits the economics Medtronic keeps talking about. Robotic surgery remains much less common outside the most developed hospital systems. A second platform could give Medtronic more freedom to match the robot to what each market can actually afford and operate.

Q6Is Cornerstone's Sentire actually cheaper than da Vinci?

Sentire has shown lower procedure costs than da Vinci in one published comparison, although the evidence is still too small for us to claim a universal cost advantage.

A peer-reviewed study compared 22 prostatectomy patients treated with Sentire with 287 patients treated with da Vinci across three high-volume Chinese hospitals. After matching comparable patients, clinical results were broadly similar.

The economic result was more interesting. Direct surgery costs were about $8,750 for Sentire versus $10,500 for da Vinci, roughly 17% lower. Sentire took longer overall, with a median operating time of 143 minutes versus 112 minutes, while console time, blood loss and several clinical outcomes were statistically similar.

Twenty-two Sentire patients is a small sample. We should treat the result as evidence that lower costs are possible, rather than a definitive estimate of how much every hospital will save.

The broader Chinese market strengthens the cost argument. MedChina's analysis of public hospital tenders found da Vinci systems averaging roughly $2.52 million in disclosed 2025 procurement deals. Major Chinese competitors averaged around $1.7 million to $2.2 million.

We do not have enough public Sentire sales to place Cornerstone cleanly inside that range. What we can say today is that Chinese surgical robotics has created real downward pressure on equipment prices, while Sentire has produced at least some clinical evidence of lower procedure costs.

Sentire and Chinese systems vs da Vinci

Q7Has Cornerstone's Sentire proved it can perform real surgery?

Sentire has passed the point where we should treat Cornerstone as a robot-demo startup, although its clinical history is still tiny compared with da Vinci.

The strongest evidence comes from patients rather than product videos. The published prostatectomy comparison found similar blood loss, positive surgical margin rates, continence outcomes and one-year PSA recurrence between Sentire and da Vinci after patient matching.

Cornerstone has also run multi-specialty clinical programs. The Chinese University of Hong Kong reported dozens of early procedures across colorectal, upper gastrointestinal and urological surgery, while CUHK Medical Centre later said more than 160 procedures had been carried out with Sentire there.

European regulatory approval added another layer of validation. Sentire's CE Mark covers general, gynecologic, thoracic and urologic procedures, giving Cornerstone a much broader commercial foundation than a robot cleared for one narrow operation.

The evidence gap with Intuitive remains huge. Da Vinci has now been used on more than 20 million patients globally. Sentire is still building evidence in hundreds of cases.

So we can be confident that Sentire is a functioning clinical surgical robot. Its reliability, economics and surgeon acceptance across thousands of installations and hundreds of thousands of procedures are another question entirely. Those are the tests that come next.

Q8Is Cornerstone Robotics already selling lots of surgical robots?

Cornerstone Robotics is commercially early today, and this may be the clearest reason Medtronic can add so much value.

MedChina's annual review of Chinese surgical robot sales found just one publicly disclosed Cornerstone laparoscopic robot tender win in 2025. The report explicitly warns that its Cornerstone figure only covers public winning bids, so we should not mistake one disclosed unit for Cornerstone's entire global installed base.

Even with that caveat, Cornerstone was far behind the most visible Chinese competitors. MicroPort MedBot's dataset showed 129 laparoscopic systems sold, including overseas sales. Edge Medical had 16 publicly disclosed tender wins, Sagebot 12 and SHURUI nine.

Cornerstone has moved faster in regulation and engineering than in sales.

That creates a very specific opportunity for Medtronic. Cornerstone already has a product, clinical data, manufacturing capacity and approvals. Medtronic brings hospital relationships, salespeople, service teams, training programs and a large existing surgical business.

If Sentire suddenly starts appearing in dozens of hospitals after entering Medtronic's network, we will have strong evidence that distribution was the missing piece. If sales remain weak, the problem was deeper.

Q9Why is Medtronic buying into Chinese surgical robotics now?

Chinese surgical robots are taking a much larger share of new hospital purchases now, so Medtronic is entering just as the local industry starts looking commercially credible.

MedChina counted 90 publicly disclosed laparoscopic robot awards in China during 2025. Chinese manufacturers won 47 of them, about 52%.

The trend moved further in the first half of 2026. Domestic manufacturers won 17 of 27 publicly disclosed endoscopic robot procurements, giving them a 63% share. In the comparable period a year earlier, Chinese systems had taken only 38%.

That is a big shift in twelve months. Overall procurement barely changed, from 26 systems to 27, while the mix moved sharply toward Chinese suppliers.

Price pressure is showing up at the same time. A recent First Financial analysis, using Huatai Securities procurement data, found that the average price paid for endoscopic surgical robots in Chinese public hospitals fell from about RMB 17.7 million to RMB 13.3 million between the comparable half-year periods, a drop of roughly 25%.

Cornerstone itself has yet to become a major winner of those tenders. Medtronic is betting on the bigger industrial change: China can now produce clinically credible surgical robots at a cost structure that is starting to disrupt the old market.

Q10How big is the market Medtronic is chasing with Sentire?

Medtronic is chasing a very large pool of surgeries that still happen without robots, especially outside the United States.

Medtronic says global adoption of robotic-assisted surgery remains in the single digits. On its latest earnings call, management also said robotic procedure volumes have grown by roughly 16% annually over the past decade.

China shows how wide the gap can become. Frost & Sullivan data cited recently by First Financial puts robot-assisted endoscopic surgery penetration at about 21.9% in the United States in 2024 and just 0.7% in China.

That is roughly a 31-fold difference.

China still performed more than 143,000 robot-assisted endoscopic procedures in that year. Moving penetration from 0.7% to even 2% or 3% would therefore create a substantial amount of additional robotic surgery without requiring China to come remotely close to U.S. adoption.

Cost is one reason the gap persists. Hospitals need to buy the robot, maintain it, train surgeons, purchase instruments and use the system frequently enough to justify the investment.

That is where Sentire starts to make sense. A platform designed around a localized Chinese supply chain may give Medtronic another way to reach hospitals where the economics of existing premium systems are difficult.

Q11Is Medtronic mainly trying to catch Intuitive Surgical?

Medtronic clearly wants to gain ground on Intuitive Surgical, and the competitive pressure has become much more intense lately.

Intuitive still sits in a different league. Its latest reported quarter included around 889,000 da Vinci procedures, up 15% year over year. The company placed 468 da Vinci systems during the quarter and finished with roughly 11,710 installed systems.

The competitive field behind Intuitive is getting more serious too.

Johnson & Johnson recently received FDA authorization for Ottava across multiple general-surgery procedures. Ottava uses robotic arms integrated into the operating table, giving hospitals another architecture to consider.

CMR Surgical is moving into the U.S. as well. CMR says its Versius system has already treated more than 45,000 patients globally.

Medtronic therefore has several competitors to worry about at once. Intuitive owns the huge installed base and surgeon ecosystem. J&J brings enormous hospital reach. CMR has accumulated real international procedure volume.

Adding Cornerstone increases the number of ways Medtronic can compete before those positions harden further.

Q12How far behind da Vinci is Medtronic's Hugo today?

Hugo is growing quickly, but Medtronic remains dozens of times smaller than Intuitive Surgical on installed robotic systems.

Medtronic expects Hugo to reach around 250 installations by the end of its fiscal year. Intuitive already has about 11,710 da Vinci systems installed.

That puts Intuitive at roughly 47 times Hugo's expected installed base.

Procedure numbers make the gap even easier to feel. Hugo is expected to cross 50,000 cumulative procedures by the end of Medtronic's fiscal year. Intuitive performed around 889,000 da Vinci procedures in its latest quarter alone.

The comparison uses different time periods, so it should not be treated as a formal market-share calculation. It still captures the size difference very well.

Medtronic does not need to beat da Vinci to build a valuable robotics business. Becoming the clear second platform across a growing global market could be enough. The current gap explains why moving faster has become so important.

Current scale of Hugo vs da Vinci

Q13Why pay $700 million for Cornerstone instead of just improving Hugo?

Medtronic is paying for years of development time, a second robot design and an existing manufacturing operation that would be extremely difficult to reproduce quickly inside Hugo.

Building another surgical robot from scratch means designing hardware and software, producing instruments, running clinical trials, getting regulatory approvals, training surgeons and building production capacity. Cornerstone has already done much of that work.

The people are part of the value too. Founder Samuel Au spent years developing surgical robotics at Intuitive, including work connected to da Vinci Single-Site and Ion. Cornerstone then built its own engineering team and supply chain around Shenzhen.

Medtronic can now attach that work to a Medical Surgical business generating more than $2 billion of quarterly revenue. The company already sells into operating rooms, trains surgeons and services complex hospital equipment.

Buying Cornerstone outright today would give Medtronic much more risk. Developing another internal platform could take years. This deal sits somewhere in the middle.

We still cannot say whether $700 million was cheap. Medtronic has disclosed neither Cornerstone's valuation nor the size of the equity stake it received. The deal becomes much easier to judge once Sentire starts producing meaningful distribution revenue, which Medtronic says should begin contributing from fiscal 2028.

Q14Is Medtronic setting itself up to buy Cornerstone Robotics later?

Medtronic has deliberately left the door open to buying Cornerstone later.

An analyst asked management directly about a possible acquisition on the latest earnings call. Medtronic stopped short of confirming any formal purchase option, while CFO Thierry Piéton said the investment gives the company "strategic optionality."

The operating arrangement tells us more than that phrase alone. Medtronic gets a board seat, starts working directly with Cornerstone and gains visibility into how the company runs. Management explicitly described this as a way to understand what is "under the hood" before considering future options.

That is a useful structure when the biggest unknown is commercialization.

Medtronic can now watch Sentire move through its own distribution network. It will see hospital demand, system utilization, service costs, instrument economics, surgeon feedback and how often Sentire competes with Hugo for the same customer.

A successful rollout would make a later acquisition much easier to defend. Weak adoption would give Medtronic a reason to keep the relationship limited.

The next few years effectively become a live commercial test of Cornerstone.

Q15What could actually make Medtronic's Cornerstone bet fail?

Medtronic's Cornerstone investment fails if Sentire remains a credible robot that hospitals rarely buy or rarely use.

That risk deserves more attention than technical performance. China already has many approved surgical robots, and commercial success is very uneven. Cornerstone's tiny disclosed tender footprint shows how far a company can progress in engineering and regulation while still struggling to build a large installed base.

Hospital economics are another problem. A cheaper robot can still be expensive once maintenance, instruments, training and operating-room time are included. Hospitals also need enough suitable procedures to keep the machine busy.

Medtronic now has two platforms to manage. Hugo and Sentire need clear enough differences that sales teams know which system fits which hospital. Too much overlap could leave Medtronic supporting two expensive robotic ecosystems while shifting customers between them.

Geopolitics could become uncomfortable as well. Cornerstone is headquartered in Hong Kong and manufactures in Shenzhen. That supply chain offers cost advantages, but medical devices with advanced robotics, software and data increasingly sit near the U.S.-China technology divide.

The final risk is simply scale. Reliable performance across hundreds of hospitals is much harder than reliable performance across a handful of clinical centers. Sentire now has to prove that its early clinical results survive mass production, repeated servicing and thousands of surgeons.

That part of the Cornerstone story is still genuinely unknown.

Q16So why is Medtronic investing in Cornerstone's Chinese surgical robot?

Medtronic is investing in Cornerstone because Sentire gives it a faster, potentially cheaper and more flexible route into a global surgical robotics market where Medtronic is still far behind Intuitive.

Hugo remains the center of Medtronic's own robotics program. The Cornerstone deal changes the strategy around it. Medtronic can now offer two different robot designs, reach international markets through a platform that already has several major approvals and experiment with economics built around a Chinese manufacturing base.

The timing makes the move more convincing. Chinese manufacturers have gone from 38% to 63% of publicly disclosed domestic endoscopic robot procurements in the comparable first-half periods. Average procurement prices are falling. Johnson & Johnson has finally brought Ottava through the FDA. CMR Surgical is entering the U.S. Intuitive is still growing da Vinci procedures by double digits from an installed base above 11,000 systems.

Waiting for Hugo alone to close that gap would be a slow strategy.

Cornerstone gives Medtronic another shot on goal while the market is still taking shape. It also gives Medtronic a close-up view of one of the more interesting things happening in medical robotics these days: Chinese engineering and manufacturing are starting to produce systems that Western medtech giants may prefer to distribute rather than recreate from scratch.

Medtronic is mainly buying speed, broader market coverage and another cost structure. At the same time, it is giving itself the chance to own more of Cornerstone later if Sentire proves that regulatory success can turn into real hospital adoption.

That commercial proof is still missing. Pretty much everything else has advanced far enough for Medtronic to place a very large bet on finding out.